Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Ferring Pharmaceuticals A/S
Femme et Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A 6-week open label cross-over study with 2 different daily doses of Minirin® oral lyophilisate (120 μg and 240 μg) and 2 different daily doses of Minirin® tablet (0.2 mg and 2 x 0.2 mg) in children and adolescents with primary nocturnal enuresis (PNE)
To evaluate the preference of subjects for Minirin® oral lyophilisate treatment compared with Minirin® tablet treatment after 6 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A follow-up study to examine the presence of anti-human growth hormone antibodies following a randomised, open-label, parallel-group, multi-centre trial (FE 999905 CS07) in which the efficacy and safety of 12 months’ treatment with one daily dose of ZOMACTON were compared to one daily dose of GENOTROPIN
To investigate the presence of remaining immunogenicity among previously anti-hGH antibody positive children who participated in the clinical trial FE 999905 CS07 and were treated with one daily dose ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
An Open-Label, Multi-Centre, Randomised Parallel-Group Dose-Finding Study, Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy
To establish the degarelix dosing regimen that most effectively achieves and maintains testosterone suppression at castrate levels during one year of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
An open-label, multi-centre, extension study evaluation the long-term safety and tolerability of Degarelix one-month depots in patients with prostate cancer
•To evaluate safety and tolerability during long-term treatment with degarelix one-month depots in prostate cancer patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
Clinical Trial Investigating Sleep Behaviour and Daytime Performance in Nocturia Patients Treated with Desmopressin Orally Disintegrating Tablets as compared to Placebo
Efficacy Objectives • To investigate the relationship between nocturia, sleep, and daytime performance • To investigate the efficacy of desmopressin orally disintegrating tablets (50 µg in men and...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
An Open-Label, Multi-Centre, Extension Study, evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens, 240 mg (40 mg/mL), 240 mg (60 mg/mL), in Patients with Prostate Cancer
To evaluate the safety and tolerability of different dosing regimens
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stimulation in women undergoing an assisted reproductive technology programme
To demonstrate non-inferiority of FE 999049 compared with GONAL-F with respect to ongoing pregnancy rate and ongoing implantation rate in the fresh cycle in women undergoing controlled ovarian stimula...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ferring Pharmaceuticals A/S (Denmark)
MAJ Il y a 5 ans
Brain development, brain functioning, growth and metabolic aspects in the clinical management of transsexual adolescents
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A study to investigate the efficacy and safety of selepressin as treatment for patients with septic shock that need vasopressor treatment
To demonstrate superiority of selepressin plus standard care versus placebo plus standard care in the number of vasopressor- and mechanical ventilator-free days (with penalty for mortality) in patient...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A randomised, assessor-blinded, multi-centre trial comparing the efficacy, safety and tolerability of the PICOPREP tailored dosing schedule to the PICOPREP day-before dosing schedule for colon cleansing in preparation for colonoscopy
To demonstrate non-inferiority of a tailored PICOPREP dosing schedule compared to the day-before PICOPREP dosing schedule in overall colon cleansing in preparation for colonoscopy
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
Suivant